Elite in Delayed Growth

Eric W. Deutsch

Gustave Roussy
Villejuif, FR 
Elite in Delayed Growth
Gustave Roussy
Villejuif, FR 
OverviewLocationsClinical Research

Overview

Eric Deutsch practices in Villejuif, France. Mr. Deutsch is rated as an Elite expert by MediFind in the treatment of Delayed Growth. His top areas of expertise are Delayed Growth, Cervical Cancer, Leukocytosis, Penectomy, and Splenectomy.

His clinical research consists of co-authoring 497 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles in the study of Delayed Growth.

Gender
Male

Locations

Gustave Roussy
Villejuif, 94805, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase I/II Study Evaluating the Safety and Clinical Activity of Anti-PDL1 (Durvalumab [MEDI4736]) + Anti CTLA-4 (Tremelimumab) Antibodies Administrated in Combination With Stereotactic Body Radiotherapy (SBRT) in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck, Lung, Oesophageus, Cervix, Vagina,Vulva or Anus
A Phase I/II Study Evaluating the Safety and Clinical Activity of Anti-PDL1 (Durvalumab [MEDI4736]) + Anti CTLA-4 (Tremelimumab) Antibodies Administrated in Combination With Stereotactic Body Radiotherapy (SBRT) in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck, Lung, Oesophageus, Cervix, Vagina,Vulva or Anus
Enrollment Status: Completed
Publish Date: May 08, 2025
Intervention Type: Drug, Radiation
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 1/Phase 2
Phase II Study, Stratified, Non-randomized, Estimating SBRT Efficiency and Toxicity in Primary and Secondary Liver Tumors
Phase II Study, Stratified, Non-randomized, Estimating SBRT Efficiency and Toxicity in Primary and Secondary Liver Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
Phase II Trial in Inoperable œsophageal Cancer Evaluating the Feasibility of the Combination of Definitive Chemoradiation With the Immune Checkpoint Blockers Nivolumab +/- Ipilimumab
Phase II Trial in Inoperable œsophageal Cancer Evaluating the Feasibility of the Combination of Definitive Chemoradiation With the Immune Checkpoint Blockers Nivolumab +/- Ipilimumab
Enrollment Status: Terminated
Publish Date: February 21, 2023
Intervention Type: Drug, Other
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
An Open-Label Multicenter Phase 1b Study of E7046 in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Subjects With Rectum Cancer
An Open-Label Multicenter Phase 1b Study of E7046 in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Subjects With Rectum Cancer
Enrollment Status: Completed
Publish Date: October 04, 2021
Intervention Type: Radiation, Drug
Study Phase: Phase 1
A Phase 1b Trial of LY2606368 in Combination With Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Cancer
A Phase 1b Trial of LY2606368 in Combination With Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Cancer
Enrollment Status: Completed
Publish Date: February 15, 2019
Intervention Type: Drug, Radiation
Study Phase: Phase 1
View 4 Less Clinical Trials

497 Total Publications

mzPeak: Designing a Scalable, Interoperable, and Future-Ready Mass Spectrometry Data Format.
mzPeak: Designing a Scalable, Interoperable, and Future-Ready Mass Spectrometry Data Format.
Journal: Journal of proteome research
Published: October 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Deutsch's expertise for a condition
ConditionClose
View All 17 Advanced Conditions
View All 29 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile